Trial reportNeuropsychiatric disease and treatment2025
Predictive Value of NT-proBNP for Functional Outcome of Ischemic Stroke Without Cardiac Disease: A Prospective, Observational Study.
Trial report in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Elevated B-Type Natriuretic Peptide as a Predictor of Unfavorable Outcomes in Post-Acute Stroke Patients.Circulation reports · 2026Article
- Early neurological rehabilitation management in a stroke patient with persistently and extremely elevated natriuretic peptides: a case report.Frontiers in medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Our study aimed to evaluate the prognostic value of NT-proBNP in predicting adverse outcomes among patients with anterior circulation infarction (ACI) and posterior circulation infarction (PCI), specifically in those without pre-existing cardiac comorbidities. Patients and Methods: This single-center, prospective observational study enrolled patients with acute ischemic stroke (AIS) within 7 days of symptom onset. We aimed to elucidate predictive role of NT-proBNP levels in determining adverse outcomes in AIS patients. Additionally, the study sought to explore the relationship between NT-proBNP levels and the risk of poor functional outcomes in both ACI and PCI patients without underlying cardiac comorbidities. Results: A total of 821 patients were included in our study. Both univariate and multivariate logistic analyses indicated that higher NT-proBNP was an independent risk factor for adverse outcomes of ischemic stroke patients at 90 days. In noncardiogenic patients, the risks of adverse outcomes during follow-up were significantly elevated in the medium and high NT-proBNP groups (medium group: OR 1.75, 95% CI 1.03-2.98, P=0.039; high group: OR 2.46, 95% CI 1.30-4.67, P=0.006), with a dose-dependent trend. The association was similarly observed in patients with isolated ACI (medium group: OR 2.02, 95% CI 1.06-3.83, P=0.031; high group: OR 2.70, 95% CI 1.25-5.79, P=0.011). High NT-proBNP levels were independently associated with END in patients without underlying cardiac comorbidities (high group: OR 2.14, 95% CI 1.06-4.31, P=0.033) and this association was also observed in ACI patients (high group: OR 5.39, 95% CI 1.70-17.04, P=0.004). Moreover, when incorporated into the clinical prediction model, NT-proBNP exhibited excellent sensitivity and specificity for predicting stroke-related functional outcomes. Conclusion: NT-proBNP demonstrates potential as a valuable biomarker in the clinical predictive model for functional outcomes specifically in ACI patients suggesting that elevated NT-proBNP levels in these patients should prompt closer monitoring and more comprehensive patient management. Trial Registration: https://www.chictr.org.cn/, ChiCTR2300067696.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.